Risk of meningioma and common variation in genes related to innate immunity.
BACKGROUND
The etiology of meningioma, the second most common type of adult brain tumor in the United States, is largely unknown. Prior studies indicate that history of immune-related conditions may affect the risk of meningioma.


METHODS
To identify genetic markers for meningioma in genes involved with innate immunity, we conducted an exploratory association study of 101 meningioma cases and 330 frequency-matched controls of European ancestry using subjects from a hospital-based study conducted by the National Cancer Institute. We genotyped 1,407 "tag" single nucleotide polymorphisms (SNP) in 148 genetic regions chosen on the basis of an r2>0.8 and minor allele frequency of >5% in Caucasians in HapMap1. Risk of meningioma was estimated by odds ratios and 95% confidence intervals.


RESULTS
Seventeen SNPs distributed across 12 genetic regions (NFKB1 (3), FCER1G (3), CCR6 (2), VCAM1, CD14, TNFRSF18, RAC2, XDH, C1D, TLR1/TLR10/TLR6, NOS1, and DEFA5) were associated with the risk of meningioma with P<0.01. Although individual SNP tests were not significant after controlling for multiple comparisons, gene region-based tests were statistically significant (P<0.05) for TNFRSF18, NFKB1, FCER1G, CD14, C1D, CCR6, and VCAM1.


CONCLUSIONS
Our results indicate that common genetic polymorphisms in innate immunity genes may be associated with risk of meningioma. Given the small sample size, replication of these results in a larger study of meningioma is needed.
Rajaraman
Preetha
P
Division of Cancer Epidemiology and Genetics, Neuro-oncology Branch, National Cancer Institute, NIH, Department of Health and Human Services, 6120 Executive Boulevard, EPS Room 7058, Bethesda, MD 20892-7238, USA. rajarama@mail.nih.gov
Brenner
Alina V
AV
Neta
Gila
G
Pfeiffer
Ruth
R
Wang
Sophia S
SS
Yeager
Meredith
M
Thomas
Gilles
G
Fine
Howard A
HA
Linet
Martha S
MS
Rothman
Nathaniel
N
Chanock
Stephen J
SJ
Inskip
Peter D
PD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D008297:Male; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000276:immunology*; D008579:Meningioma / Q000235:genetics* / Q000276:immunology*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult
D009363:Neoplasm Proteins
PLoS One. 2009;4(4):e5360
19390683
Neurotherapeutics. 2009 Jul;6(3):427-35
19560733
Cancer Lett. 2002 Dec 15;188(1-2):103-7
12406554
Pharmacogenet Genomics. 2006 Nov;16(11):783-8
17047486
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86
19223558
Genet Epidemiol. 2003 Dec;25(4):360-6
14639705
Neurosurgery. 2000 Nov;47(5):1185-95
11063113
J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
17925535
Nat Rev Immunol. 2005 Nov;5(11):866-79
16261174
Immunol Rev. 2006 Oct;213:195-212
16972905
J Anat. 2005 Sep;207(3):265-9
16185251
N Engl J Med. 2001 Jan 11;344(2):79-86
11150357
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8
19423540
Nature. 2003 Dec 18;426(6968):789-96
14685227
Cancer. 1999 Dec 15;86(12):2649-58
10594860
Am J Epidemiol. 2007 Mar 1;165(5):477-85
17182979
J Immunol. 2009 Mar 1;182(5):3131-8
19234210
Histol Histopathol. 2007 Dec;22(12):1387-98
17701919
PLoS Genet. 2008 Aug;4(8):e1000166
18846228
Dement Geriatr Cogn Disord. 2008;26(3):247-50
18841008